NSABP P-2: STAR

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In the P-1 study, tamoxifen was shown to prevent the development of invasive and in situ breast cancer. Raloxifene has shown to be an effective drug for the prevention of osteoporosis. It was observed in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial that there were fewer breast cancers in the group of patients that had taken raloxifene compared to the controls. This study will determine if raloxifene is either more or less effective than tamoxifen in reducing the incidence of invasive breast cancer in postmenopausal women who are at increased risk for the disease. A secondary goal is to determine whether raloxifene reduces the endometrial cancer rate compared to tamoxifen.